Empressin in the management of septic shock
Normaler Preis
SFr. 0.00
Angebot
Septic shock is the most common cause of death in intensive care units (ICUs) and has a mortality rate of 40 to 60%. Resuscitation strategies include the administration of intravenous fluids and the use of cate-cholamines.
Vasopressin, an endogenous peptide hormone, has emerged as an adjunct to catecholamines for patients who have severe septic shock. Despite the widespread use of vasopressin in clinical practice, there are limited randomised clinical trials to evaluate its use in patients with septic shock. Furthermore, the Surviving Sepsis Campaign (SSC) Guidelines include vague recommendations on the use of vasopressin. While awaiting further clinical evidence for the use of vasopressin in septic shock, expert panellists across Switzerland gathered to form vasopressin treatment recommendations for local ICU use.
The Empressin Swiss expert panellist group was convened in December 2019 to support discussions around recommending an Empressin treatment algorithm for physicians in Switzerland. During a face-to-face meeting, key recommendations were formed on vasoplegia diagnosis, treatment initiation, treatment effect on mortality, treatment weaning and the target patient population.
This expert panel opinion report discusses these five key points with the aim to provide clarity to Swiss ICU physicians who manage patients with septic shock. This report should elucidate vague international recommendations before further specific guidelines are published.
Vasopressin, an endogenous peptide hormone, has emerged as an adjunct to catecholamines for patients who have severe septic shock. Despite the widespread use of vasopressin in clinical practice, there are limited randomised clinical trials to evaluate its use in patients with septic shock. Furthermore, the Surviving Sepsis Campaign (SSC) Guidelines include vague recommendations on the use of vasopressin. While awaiting further clinical evidence for the use of vasopressin in septic shock, expert panellists across Switzerland gathered to form vasopressin treatment recommendations for local ICU use.
The Empressin Swiss expert panellist group was convened in December 2019 to support discussions around recommending an Empressin treatment algorithm for physicians in Switzerland. During a face-to-face meeting, key recommendations were formed on vasoplegia diagnosis, treatment initiation, treatment effect on mortality, treatment weaning and the target patient population.
This expert panel opinion report discusses these five key points with the aim to provide clarity to Swiss ICU physicians who manage patients with septic shock. This report should elucidate vague international recommendations before further specific guidelines are published.